Humoral transplantation antibodies

Milgrom, Felix

doi:10.1016/s0041-1345(98)02060-0

Cited by 4 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While antibodies received early attention as a major mechanism of allograft injury (1,2), the major focus of recent immunosuppressive drug development has been on agents that block the T-cell pathway. These anti-T-cell agents have significantly reduced the rate of acute rejection and enhanced 1-year graft survival, but long-term graft survival, as measured by graft half-life, has had only a marginal increase.…”

Section: Introductionmentioning

confidence: 99%

Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action

Pescovitz

2006

American Journal of Transplantation

537

352

View full text Add to dashboard Cite

Rituximab, chimeric anti-human CD20, is approved for treatment of B-cell lymphoma in adults. It is being used experimentally in other various immune-related diseases such as immune thrombocytopenic purpura, systemic lupus erythematosus, myasthenia gravis and rheumatoid arthritis. In transplant recipients, it is used for treatment of post-transplant lymphoproliferative disease, to anecdotally reduce pre-formed anti-HLA and anti-ABO antibodies and for the prevention and treatment of acute rejection. This article primarily reviews the science behind rituximab: its history, pharmacokinetics and potential mechanism of action. A need for controlled clinical trials is clearly indicated before the widespread use of this drug in transplant.

show abstract

Section: Introductionmentioning

confidence: 99%

Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action

Pescovitz

2006

American Journal of Transplantation

537

352

View full text Add to dashboard Cite

show abstract

“…While antibodies received early attention as a major mechanism of allograft injury (1, 2), the major focus of immunosuppressive drug development has been on agents that block the T‐cell pathway. These anti‐T‐cell agents have significantly reduced the rate of acute rejection and enhanced 1‐yr graft survival, but long‐term graft survival, as measured by graft half‐life, has had only a marginal increase.…”

mentioning

confidence: 99%

The use of rituximab, anti‐CD20 monoclonal antibody, in pediatric transplantation

Pescovitz

2004

Pediatric Transplantation

View full text Add to dashboard Cite

Rituximab, chimeric anti-human CD-20, is approved for treatment of B-cell lymphoma in adults. It is being used experimentally in other various immune-related disease such as immune thrombocytopenic purpura, myasthenia gravis, and rheumatoid arthritis. In transplant recipients it is used for treatment of post-transplant lymphoproliferative disease, and prevention and treatment of acute rejection. There are few data on its use in children. This paper reviews the use of rituximab in these disease states and provides hypotheses for its mode of action.

show abstract

Rituximab, an Anti‐CD20 Monoclonal Antibody

Pescovitz

2010

Immunotherapy in Transplantation

View full text Add to dashboard Cite

Humoral transplantation antibodies

Cited by 4 publications

References 28 publications

Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action

Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action

The use of rituximab, anti‐CD20 monoclonal antibody, in pediatric transplantation

Rituximab, an Anti‐CD20 Monoclonal Antibody

Contact Info

Product

Resources

About